Year: 2015
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: People with Parkinson disease (PD) frequently develop dementia, which is associated with neocortical deposition of alpha-synuclein (α-syn) in Lewy bodies and Lewy neurites. In addition, neuronal loss and deposition of aggregated α-syn also occur in multiple subcortical nuclei that project to neocortical, limbic, and basal ganglia regions. Therefore, we quantified regional deficits in innervation from these PD-affected subcortical nuclei, by measuring the neurotransmitters and neurotransmitter transporter proteins originating from projections of dopaminergic neurons in substantia nigra pars compacta, serotonergic neurons in dorsal raphé nuclei, noradrenergic neurons in locus coeruleus, and cholinergic neurons in nucleus basalis of Meynert. METHODS: High-performance liquid chromatography and novel enzyme-linked immunosorbent assays were performed to quantify dopaminergic, serotonergic, noradrenergic, and cholinergic innervation in postmortem brain tissue. Eight brain regions from 15 PD participants (with dementia and Braak stage 6 α-syn deposition) and six age-matched controls were tested. RESULTS: PD participants compared to controls had widespread reductions of dopamine transporter in caudate, amygdala, hippocampus, inferior parietal lobule (IPL), precuneus, and visual association cortex (VAC) that exceeded loss of dopamine, which was only significantly reduced in caudate and amygdala. In contrast, PD participants had comparable deficits of both serotonin and serotonin transporter in caudate, middle frontal gyrus, IPL, and VAC. PD participants also had significantly reduced norepinephrine levels for all eight brain regions tested. Vesicular acetylcholine transporter levels were only quantifiable in caudate and hippocampus and did not differ between PD and control groups. INTERPRETATION: These results demonstrate widespread deficits in dopaminergic, serotonergic, and noradrenergic innervation of neocortical, limbic, and basal ganglia regions in advanced PD with dementia.
DOI: 10.1002/acn3.246
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: Parkinson's disease, Parkinson's disease dementia, dopaminergic innervation, serotonergic innervation, noradrenergic innervation, cholinergic innervation, dopamine transporter, serotonin transporter, norepinephrine, vesicular acetylcholine transporter, alpha-synuclein, Lewy bodies, Lewy neurites, substantia nigra pars compacta, dorsal raphe nucleus, locus coeruleus, nucleus basalis of Meynert, caudate nucleus, amygdala, hippocampus, inferior parietal lobule, visual association cortex, Braak stages
Open Access status: gold
Estimated APC paid: $4,100
Funders: Michael J. Fox Foundation for Parkinson's Research, American Parkinson Disease Association, Washington University in St. Louis, National Institutes of Health, McDonnell Center for Systems Neuroscience, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences
Awards: Investigations of Dementia in Parkinson Disease, Neurodegenerative consequences of PanK2 mutations, G611383016, G6637773844, MECHANISMS OF DEEP BRAIN STIMULATION, Alzheimer's Disease Research Center, Investigations of Dementia in Parkinson Disease, Healthy Aging and Senile Dementia, Washington University Institute of Clinical and Translational Sciences, VALIDATION OF NEUROIMAGING BIOMARKERS FOR NIGROSTRAITAL NEURONS, G9000115080, G9000265048
OpenAlex ID: W2158625734
